Home Blog Page 1061

DIFF Biotech’s Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway

By
Advertorial Desk
-

HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ — Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval as a Class 1.2 innovative vaccine from China’s National Medical Products Administration (NMPA).

As the first domestically self-developed nasal spray influenza vaccine in China to advance into clinical trial, DIFF-flu leverages a pioneering M2 gene–modified attenuation technology, protected by multiple international invention patents. This achievement underscores DIFF Biotech’s leading capabilities in respiratory infectious disease prevention and establishes an important foundation for future industrialization.

Dr. Jiasheng Song, Chief Executive Officer of DIFF Biotech, commented: “DIFF-flu’s clinical approval marks a major milestone for DIFF Biotech and a meaningful achievement for independent innovation in respiratory infectious disease prevention. As a next-generation attenuation platform, DIFF-flu is designed to achieve an optimal balance between immunogenicity and safety—an advance that holds significant potential for improving influenza protection. We believe this progress will help expand access to safer, more effective influenza prevention, particularly for older adults and other vulnerable populations. DIFF Biotech will continue to drive next-generation vaccine innovation to strengthen public health and contribute to global biomedical progress.”

A New Attenuation Strategy: Replication Restriction for Enhanced Safety

DIFF-flu is developed using an innovative M2 gene–modification strategy that produces a replication-restricted vaccine strain. This approach achieves a deliberate balance between robust attenuation and strong immunogenicity—generating a potent immune response while maintaining an exceptional safety profile. In essence, the technology places a “safety harness” on the virus to prevent uncontrolled replication.

Existing nasal spray influenza vaccines on the market rely on cold-adapted attenuation, allowing the vaccine virus to replicate efficiently only at lower temperatures such as those in the nasal cavity but limiting replication in the warmer lower respiratory system and lungs. Because these strains can still replicate in nasal mucosa and cause mild viral shedding, they are generally not recommended for older adults or immunocompromised individuals.

Preclinical data indicate that DIFF-flu offers a differentiated safety profile, with negligible viral shedding, and significantly reduced viral loads in respiratory tissues, suggesting the potential to extend nasal spray vaccine eligibility to older adults and other underserved groups.

Notably, preclinical data show that DIFF-flu confers 100% protection against epidemic strains circulating more than 50 years ago, while also eliciting strong immunity against contemporary variants.

Market Landscape: At-Home Use Policies Unlock Global Opportunities

The global influenza vaccine market is undergoing a period of structural evolution. While injectable vaccines remain the predominant format, they continue to face long-standing challenges such as suboptimal uptake and limited ability to curb viral transmission. Nasal spray vaccines—which induce mucosal immunity directly at the site of viral entry—represent an increasingly important direction for influenza prevention.

In September 2024, the U.S. FDA granted authorization for at-home administration of a related nasal spray influenza vaccine, paving the way for direct-to-consumer (DTC) distribution models. This regulatory milestone significantly improves convenience and accessibility for the public and creates favorable conditions for DIFF-flu’s future global introduction.

Global Influenza Burden Underscores the Need to Strengthen Herd Immunity

According to the World Health Organization (WHO), seasonal influenza infects up to 1 billion people each year, causing 3–5 million severe cases and 290,000–650,000 respiratory deaths globally.

Older adults account for the majority of influenza-related deaths and face heightened risks of complications such as pneumonia, myocarditis, encephalitis, and acute cardiorespiratory failure. Studies show that influenza vaccination can reduce hospitalization risk by 40–60%, making improved vaccine coverage especially critical for aging and medically vulnerable populations.

Despite this, vaccination rates remain low in many parts of the world. In China, influenza vaccination coverage is approximately 3.8%, far below mature markets such as the United States (around 49.3%). Increasing vaccination uptake is essential to protect high-risk groups and strengthen community-level immunity.

About DIFF Biotech

Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) is a clinical-stage biotechnology company specializing in its proprietary Viraltech Architect Platform. Leveraging this platform, the company has built an integrated, end-to-end capability for the development of differentiated biologics. DIFF Biotech has filed over 70 domestic and international invention patents, including more than 10 PCT applications, and has received multiple honors such as the 23rd China Excellent Patent Award, “High-tech Enterprise” and “Quasi-Unicorn” enterprise.

The company’s R&D efforts span mucosal vaccines, antiviral drugs, oncolytic viruses, and gene therapy products. Its vaccine pipeline—powered by proprietary attenuation technologies—effectively establishes the body’s first line of defense at the mucosal barrier, offering clear competitive differentiation. In the oncolytic virus and gene therapy domains, DIFF Biotech has built distinctive capabilities in vector targeting, controllable replication, and high-efficiency gene delivery, enabling the development of advanced, next-generation biologics.

 For more information, please visit https://en.diff-biotech.com/.

E-mail: BD@diff-biotech.com 

 

BioDlink Recognized by Client for Enabling the World’s First Dual-Payload ADC to Enter Clinical Trials

By
Advertorial Desk
-
  • BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development.
  • BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution.

SUZHOU, China, Feb. 9, 2026 /PRNewswire/ — BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group (“Kanghong Pharmaceutical”), recognizing BioDlink’s critical contribution to the successful clinical approval of KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development.

KH815 is a first-in-class dual-payload ADC independently developed by Kanghong Pharmaceutical. The program achieved a major regulatory milestone with approval from Australia’s Human Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025.

As Kanghong Pharmaceutical’s CDMO partner, BioDlink supported the program across the full development lifecycle, including process development, analytical method development and validation, and formulation research.

Efficient Execution of a Complex First-in-Class Program

KH815 required advanced process design and analytical control, including precise management of drug-to-antibody ratio (DAR) and comprehensive product characterization. Leveraging its expertise in complex ADC development, BioDlink delivered a robust, scalable, and reproducible manufacturing solution despite limited material availability and aggressive timelines.

Despite the complexity of conjugation process development and analytical characterization, BioDlink applied strong technical expertise to define and lock robust process and analytical strategies, enabling successful scale-up and batch release. Through continuous process optimization, development, manufacturing, and regulatory submission activities were completed 1.5 months ahead of plan, exceeding client expectations and demonstrating strong execution capability, which earned high recognition from Kanghong Pharmaceutical for BioDlink’s technical expertise and service excellence.

Advancing Innovation in ADC Development

The successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close collaboration across industry and research. BioDlink remains committed to providing end-to-end CDMO services to global partners, accelerating the development of complex biologics from early development through commercialization.

About Kanghong Pharmaceutical
Kanghong is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, neuropsychiatric and others.

Kanghong is devoted to the lives of patients through high quality, innovation and responsibility. Since its establishment, the company keeps researching, producing, and commercializing safer and more efficient drugs for pressing unmet medical needs.

The company’s purpose is to fundamentally improve patients’ physical ability and social medical efficacy by using innovative science and breakthrough treatments to achieve  progress in human health.

About BioDlink
BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D through commercial manufacturing.

With its one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs.

The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, Colombia and Bolivian.

Guided by the philosophy of “Quality First, Innovation Driven, Success Together”, BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: https://biodlink.com/ 

Acer Announces January 2026 Revenues at NT$21.08 Billion, Up 39.8% Year-on-year, Highest January Revenue Post Pandemic

By
Advertorial Desk
-

TAIPEI, Feb. 9, 2026 /PRNewswire/ — Acer Inc. (TWSE: 2353) announced its consolidated revenues for January 2026 at NT$21.08 billion, up 39.8% year-on-year (YoY), the highest January revenue post pandemic.

Highlights in January include:

  • Revenues from notebook PCs grew by 50.6% YoY
  • Revenues from desktop PCs grew by 41.9% YoY
  • Revenues from gaming products and businesses grew by 53.4% YoY
  • Revenues from the commercial line [1] grew by 63.4%

Acer’s strategy to expand multiple business engines continued to gain momentum. Total revenues from businesses other than personal computers [2] and displays contributed 42.1% of the group’s total revenues in January. Acer’s public subsidiaries have announced their January revenues; some highlights for businesses under incubation include Acer ITS Inc. with revenues growth of 83.0% year-on-year in January.

The Acer Chromebooks released during the BETT 2026 education technology exhibition in London were well received by the media, who highlighted their durable designs and repairability features that are beneficial for school teaching and IT teams for repairs. Acer ranked among the top 3 in the global Chromebook market, and No. 1 in EMEA in full year 2025 [3].

[1] Acer’s commercial products, excluding Chromebooks
[2] Personal computers business includes desktops and notebooks
[3] IDC Preliminary Historical Q4’25 PC report

About Acer

Founded in 1976, Acer is one of the world’s top technology companies with a presence in more than 160 countries. The company continues to evolve by embracing innovation across its offerings, which include computers and displays, while branching out to new businesses. Acer is also committed to sustainable growth, exploring new opportunities that align with its environmental and social responsibilities. The Acer Group employs nearly 12,000 employees that contribute to the research, design, marketing, sales and support of products, solutions, and services that break barriers between people and technology. Visit www.acer.com for more information.

© 2026 Acer Inc. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra.

DAR GLOBAL DEBUTS NICKELODEON HOTELS & RESORTS OMAN IN AIDA, THE ICONIC BRAND OF FAMILY ENTERTAINMENT

By
Advertorial Desk
-

MUSCAT, Sultanate of Oman, Feb. 9, 2026 /PRNewswire/ — Dar Global, the London-listed luxury real estate developer, has unveiled Nickelodeon Hotels & Resorts Oman at its landmark AIDA development. The project marks a significant addition to Oman’s fast-growing tourism sector, redefining luxury family travel while presenting a distinctive investment opportunity within one of the Sultanate’s most ambitious destinations.

DAR GLOBAL DEBUTS NICKELODEON HOTELS & RESORTS OMAN IN AIDA, THE ICONIC BRAND OF FAMILY ENTERTAINMENT
DAR GLOBAL DEBUTS NICKELODEON HOTELS & RESORTS OMAN IN AIDA, THE ICONIC BRAND OF FAMILY ENTERTAINMENT

Located 130 metres above sea level within AIDA’s clifftop community, the resort blends high-end hospitality with immersive, family-focused entertainment. The Nickelodeon Hotel will feature 120 keys, comprising furnished themed luxury suites and family-oriented rooms ranging from one-bedroom units to expansive three-bedroom residences, each designed with bold character and playful detailing inspired by Nickelodeon’s globally recognised brands.

Guests and residents will enjoy access to Aqua Nick, a signature waterpark with slides and splash zones, alongside themed dining concepts, Club Nick—the hotel’s dedicated kids-only clubhouse—and a programme of live entertainment including interactive game shows, character appearances and Nickelodeon’s iconic slime experiences.

For investors, the project offers full title ownership within a globally recognised branded family hospitality concept, designed to drive strong demand, long-term appeal and attractive returns.

Nickelodeon Hotels & Resorts Oman forms part of the wider AIDA masterplan, a joint venture between Dar Global and Omran Group, Oman’s leading tourism development entity. Spanning 3.5 million square metres, AIDA integrates luxury golf, residential and hospitality offerings, including mansions, limited-edition villas and premium apartments, reinforcing Oman’s positioning as a destination for high-quality living, tourism and investment.

Ziad El Chaar, CEO of Dar Global, said: “AIDA is a milestone project that elevates Oman’s luxury real estate landscape and supports long-term economic growth. The introduction of Nickelodeon Hotels & Resorts Oman reflects our commitment to delivering distinctive destinations and compelling investment opportunities aligned with global demand.”

Marie Marks, Senior Vice President, Global Experiences, Paramount, added: “Nickelodeon Hotels & Resorts Oman will offer families and fans an unforgettable destination, combining world-class entertainment with thoughtfully designed accommodation that creates lasting memories.”

Aligned with Oman Vision 2040, the development supports national objectives to expand tourism and diversify GDP. With the first phase of AIDA, including core infrastructure, scheduled for completion by 2027, early investors stand to benefit from entry into a rapidly emerging luxury destination supported by Dar Global’s proven track record in branded residential and hospitality developments.

AV-Comparatives Publishes Security Survey 2026: Global Trends in Cybersecurity Adoption and Threat Perception

By
Advertorial Desk
-

INNSBRUCK, Austria, Feb. 9, 2026 /PRNewswire/ — AV-Comparatives, the leading independent authority on cybersecurity testing and research, today announced the release of the Security Survey 2026, a comprehensive global study capturing current user behavior, technology preferences, and threat perceptions in IT security. Based on responses from 1,328 participants across 87 countries, the survey provides a data-driven snapshot of how individuals and organizations approach digital protection in an evolving threat landscape.

 

 

Most-Used Desktop Security Solutions

One of the key findings of the survey is the continued reliance on a small group of established desktop security vendors. A clear majority of respondents report using commercial or paid security solutions, indicating a sustained preference for comprehensive protection over free alternatives. Among the most widely used desktop security products are Bitdefender, Kaspersky and ESET, with Microsoft’s security solutions also playing a significant role.

These results underline the importance of trust, brand recognition and proven testing results in users’ security choices, while also revealing regional differences in vendor adoption.

Operating Systems and Platform Trends

The survey highlights ongoing shifts in operating system usage. Windows 11 is now the most used desktop operating system among respondents, reflecting continued migration away from older, now unsupported, Windows versions. In parallel, the data shows that Linux usage has reached levels comparable to macOS within the survey population, suggesting a growing acceptance of Linux as a viable desktop platform among security-aware users.

On mobile devices, Android maintains its dominant position globally, while iOS continues to attract a strong user base, particularly among professionals and advanced users.

Perceived Sources of Cyberattacks

Beyond technology adoption, the Security Survey 2026 provides insight into how users perceive global cyber threats. When asked which countries they most fear as potential sources of cyberattacks, respondents most frequently named Russia and China, followed by the United States and North Korea.

Additionally, a notable proportion of participants expressed concern about domestic surveillance and internal threats within their own countries.

Practical Insights for the Security Community

While the survey is not intended to represent the global population as a whole, it offers valuable insights for cybersecurity professionals, vendors, researchers and policymakers. Trends such as the continuing preference of commercial security solutions, the dominance of Windows 11, the growing relevance of Linux, and evolving perceptions of state-sponsored threat actors provide meaningful context for strategic decision-making.

Access the Full Report

The AV-Comparatives Security Survey 2026 is available free of charge and without registration at:
https://www.av-comparatives.org/av-comparatives-security-survey-2026-published/

Cango Inc. Releases 2025 Letter to Shareholders

By
Advertorial Desk
-

DALLAS, Feb. 9, 2026 /PRNewswire/ — Cango Inc. (NYSE: CANG) today released a letter to shareholders highlighting its strategic transformation and roadmap to evolve from a global Bitcoin miner into an AI compute infrastructure platform.

Throughout the past year, Cango executed a disciplined entry into the industry, balancing speed with operational prudence to build its position as a leading Bitcoin miner with a global footprint across four key regions. Key commitments were delivered, including acquiring and enhancing hashrate efficiency of 50 EH/s of on-rack machines, adopting a strategic treasury approach, divesting legacy operations, securing 50 MW of energy infrastructure, and completing the transition to a direct NYSE listing. These milestones established the foundation for Cango’s transition from hosted hashpower toward a global distributed inference compute grid.

In response to market conditions, Cango made a treasury adjustment to strengthen the balance sheet and reduce financial leverage, creating increased capacity to fund strategic expansion into AI compute infrastructure.

The Strategic Logic behind the Proposed Pivot

Cango’s global mining operations, operational experience, and infrastructure provide a practical pathway toward AI compute objectives. The rapidly growing AI era continues to face a “Power Gap”—a disconnect between rising compute demand and existing grid capacity. By leveraging globally accessed, grid-connected infrastructure, Cango is positioned to deliver flexible, high-performance compute capacity to meet long-tail inference demand through a scalable business model.

This transition follows a disciplined three-phase roadmap:

Near Term: Standardization and efficient deployment of modular, containerized GPU nodes for rapid deployment, offering on-demand compute capacity.

Medium Term: Deployment of a proprietary software platform for orchestration, evolving Cango into an integrated, enterprise-grade network enabler.

Long Term: Global scaling into a mature AI infrastructure platform, activating underutilized power to establish durable, recurring revenue streams.

To accelerate this transition, Cango has established EcoHash Technology LLC, a wholly-owned subsidiary based in Dallas, Texas, dedicated to advancing AI compute initiatives under the leadership of a newly appointed AI CTO.

The Company also positions itself as an “Ecosystem Enabler” for the wider mining industry, providing a practical technical path to adapt existing energy infrastructure for AI operations with manageable upfront commitment.

Cango acknowledges this shift is a multi-year journey, but believes its infrastructure and operational experience provide a clear path to open new, durable revenue streams while complementing its core mining operations.

View original content: https://ir-image.cangoonline.com/ir-documents/2026-02-09_Cango-Inc-Releases-2025-Letter-to-Shareholders.pdf

Investor Relations Contact

Juliet YE, Head of Communications
Cango Inc.
Email: ir@cangoonline.com 

‘Made in India – The story of Desh Bandhu Gupta, Lupin and Indian Pharma’ Book Launched in Mumbai

By
Advertorial Desk
-

MUMBAI, India, Feb. 9, 2026 /PRNewswire/ — Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India’s pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordinary life of its founder, Desh Bandhu Gupta. Together, the three journeys illuminate how a country once completely dependent on imported medicines became the world’s pharmacy. The book shares how an individual’s life, shaped early by adversity, growing up without privilege or patronage, unpredictably nurtured hunger and drive, to navigate an unforgiving state, blend national health priorities and global standards, to build a multibillion-dollar enterprise whose medicines reach patients in over 120 countries.

(L to R) - Dilip Shanghvi, Sun Pharma; Dr. Yusuf Hamied, Cipla; G.V. Prasad, Dr. Reddy’s; Prof. M. M. Sharma, Ex-(UDCT) ICT; Vinita Gupta, Lupin; Moderator, Manish Sabharwal.
(L to R) – Dilip Shanghvi, Sun Pharma; Dr. Yusuf Hamied, Cipla; G.V. Prasad, Dr. Reddy’s; Prof. M. M. Sharma, Ex-(UDCT) ICT; Vinita Gupta, Lupin; Moderator, Manish Sabharwal.

Made in India shows the distance travelled by a village boy from Rajasthan, who went on to become a teacher, professor and pharmaceutical employee, before founding a company worth $10 billion. It is the story of how an unlikely entrepreneur, given his role models, fought the system and left teaching and pharma jobs, going on to build a successful company, giving wings to a world-class industry and became a business icon for a nation.

Written with candor by TeamLease Services co-founder Manish Sabharwal and journalist Sundeep Khanna, the book confronts failures, financial crises, and the personal toll of leadership, alongside achievement and success, in the building of one of the world’s biggest generics firms. This is a riveting portrait of entrepreneurship without mythmaking – of how institutions are built slowly, tested severely and rebuilt with resolve. Made in India weaves vivid anecdotes tracing Desh Bandhu Gupta’s transformation from a humble professor to a pharma titan, finding his true calling in tending to the unmet needs of people. It issues a powerful call to future leaders, showcasing his journey of visionary entrepreneurship: rising from setbacks with raw grit and unshakeable conviction. 

Made in India also spotlights Desh Bandhu Gupta’s wife Manju Gupta’s pivotal role amid the trials and triumphs of building Lupin. Together, the couple also built community service and rural support programs, even as Lupin and India became a reliable global supplier of pharmaceuticals.

India has today become the world’s pharmacy: Nearly half of the 400 billion pills Americans consume every year are made in India, as are 60 per cent of the world’s vaccines. Of the 700 US Food and Drug Administration-approved factories that sell medicines in the US, a third are located in India. The co-creators of Indian pharma – Dr. Yusuf Hamied (Cipla), Anji Reddy (Dr. Reddy’s), Parvinder Singh (Ranbaxy), Dilip Shanghvi (Sun), Ramanbhai Patel (Zydus-Cadila), Habil Khorakiwala (Wockhardt) and DBG (Lupin) – matter more to India than their companies’ revenues, exports or profits because they saw something no one else did. Together, they raised India’s soft and hard power, demolished the myth that multinationals possess unfair advantages over Indian companies, and ended pessimism about India’s ability to export goods, making pharma India’s biggest manufacturing success. Together, they showed the world that a developing nation can dominate a complex industry when brilliant entrepreneurs meet smart policy. Together, they made India ‘Pharmacy to the world’.

Made in India came alive during the launch as the authors, and the publisher shared their journeys, followed by a rich and engaging panel discussion on ‘Past and Future of Indian Pharma’ with pharma leaders Dilip Shanghvi, Sun Pharma, Dr. Yusuf Hamied, Cipla, G.V. Prasad, Dr. Reddy’s, Vinita Gupta, Lupin, and Prof. M. M. Sharma, Ex-(UDCT) ICT. The panel discussed insights on leadership, nation-building, and the Indian pharma industry’s crucial role in making healthcare affordable and accessible globally. 

Praise for the book:

Dilip Sanghvi of Sun Pharma said, “DBG was a visionary whose heart beat for India and for Indian patients. His relentless focus on excellence defined his personality. He was a remarkable role model for all of us and one of the true architects who helped shape India’s journey to becoming the pharmacy to the world”.

Yusuf Hamied of Cipla said, “DBG built Lupin from extremely modest beginnings, guided by determination and a deep commitment to serving patients. DBG’s life story is not only inspiring, but also a reminder of how one individuals purpose can make healthcare accessible and affordable across the world”.

Made in India is a book for everyone thinking about India’s place in the world, seeking role models of a world leading industry from India, entrepreneurs and business people looking for inspiration about building a valuable company, and finally, India’s young and their parents, aiming to build ambition, exploration and determination. 

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Lupin Human Welfare and Research Foundation has impacted more than 2.02 million beneficiaries across 5400 villages in 26 districts, spread across eight states in India.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin 

(L to R) - Author Sundeep Khanna; Chiki Sarkar, Juggernaut Books;Manju D Gupta, Lupin;Dilip Shanghvi, Sun Pharma; Vinita Gupta, Lupin; Dr. Yusuf Hamied, Cipla; Prof. M. M. Sharma, Ex-(UDCT) ICT; G.V. Prasad, Dr. Reddy’s;Nilesh Gupta, Lupin; Author Manish Sabharwal.
(L to R) – Author Sundeep Khanna; Chiki Sarkar, Juggernaut Books;Manju D Gupta, Lupin;Dilip Shanghvi, Sun Pharma; Vinita Gupta, Lupin; Dr. Yusuf Hamied, Cipla; Prof. M. M. Sharma, Ex-(UDCT) ICT; G.V. Prasad, Dr. Reddy’s;Nilesh Gupta, Lupin; Author Manish Sabharwal.

 

Intrepid Announces C$6.5 million Non-Brokered Private Placement

By
Advertorial Desk
-
Vancouver, British Columbia – Newsfile Corp. – February 9, 2026 – Intrepid Metals Corp. (TSXV: INTR) (OTCQB: IMTCF) (“Intrepid” or the “Company”) is pleased to announce that it has arranged a non-brokered private placement (the “Offering“) for gross proceeds of up to C$6.5 million of common shares (the “Shares“) at a price of C$0.60 per Share (the “Issue Price“). Teck Resources Limited (“Teck“) has agreed to participate in the Offering and subscribe for 6,842,881 Shares, for gross proceeds of approximately C$4.1 million, in accordance with the terms of a subscription agreement entered into by the Company and Teck. Upon closing of the Offering (and assuming the completion of the maximum offering amount under the Offering), Teck will hold approximately 15% of the issued and outstanding Shares on a non-diluted basis. The Offering is subject to customary conditions precedent, including receipt of all required regulatory approvals.

The increased investment builds on Teck’s initial strategic position announced in December 2025 and reflects continued technical and strategic engagement between Intrepid and Teck.

“Teck’s decision to increase its investment in Intrepid is a strong endorsement of the quality, scale, and emerging potential of the Corral Copper Project (“Corral” or the “Project“),” said Mark Morabito, Chairman and Chief Executive Officer of Intrepid. “This additional investment reflects growing confidence in our systematic, district-scale approach. The funding provides a clear runway to execute a comprehensive, multi-year exploration and development program while maintaining strong alignment with a leading global mining company.”

Proceeds from the Offering will be used to complete an initial 30-month exploration and development program at Corral (the “Committed Program“) as well as for annual property option and rental payments to keep the properties in good standing. The Committed Program is expected to include, among other work programs, a 50 line-kilometre induced polarization (“IP“) survey, geological mapping and geochemical sampling, metallurgical and permitting work, and follow-up drilling designed to expand known zones and test new targets identified by Intrepid’s integrated, multi-dataset targeting. Intrepid anticipates additional mapping, geophysics, geochemical sampling and drilling at Corral in H2 2026.

Upon closing of the Offering, the Company and Teck will enter into an amendment (the “Amendment“) to the investor rights agreement entered into on December 23, 2025 (the “Investor Rights Agreement“). Pursuant to the Amendment, the parties will agree to: (i) increase the amount of Committed Funds applicable to the Committed Program; (ii) extend the timelines for the Committed Program and Teck’s right of first refusal on the Corral Project by six months; (iii) increase Teck’s participation rights and maximum ownership from 15% to 19.9%, and (iv) to provide no-more-favourable protection for the participation rights in the Investor Rights Agreement.

The Offering is subject to certain closing conditions, including, but not limited to, the receipt of all necessary approvals, including the conditional approval of the Exchange. The Offering will close upon receipt of Exchange approval.

The Shares issued under the Offering will be subject to a statutory hold period under applicable securities laws in Canada expiring four months and one day from closing of the Offering.

Haywood Securities Inc. is acting as financial advisor and Farris LLP is acting as legal counsel to the Company.

As of the date hereof, Teck beneficially owns, directly or indirectly, or exercises control or direction over, 8,800,000 Shares, representing approximately 9.38% of the issued and outstanding Shares on a non-diluted basis. Upon closing of the Offering (and assuming the completion of the maximum offering amount under the Offering), Teck will beneficially own, directly or indirectly, or exercise control or direction over, 15,642,881 Shares, representing approximately 14.95% of the issued and outstanding Shares on a non-diluted basis.

Teck’s purchase of the Shares under the Offering is being made for investment purposes. Teck may determine to increase or decrease its investment in the Company depending on market conditions and any other relevant factors. This release is required to be issued under the early warning requirements of applicable securities laws. Teck’s head office is located at Suite 3300 – 550 Burrard Street, Vancouver, BC, V6C 0B3. In satisfaction of the requirements of the National Instrument 62-104 – Take-Over Bids And Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, early warning reports respecting the acquisition of Shares by Teck or its affiliates will be filed under the Company’s SEDAR+ at www.sedarplus.ca. A copy of Teck’s early warning report to be filed in connection with the Offering may also be obtained by contacting Dale Steeves at 236-987-7405.

Board Update

The Company also announces that Mr. Matt Lennox-King has resigned from the Board of Directors of Intrepid, effective immediately. The Board would like to thank Mr. Lennox-King for his services and contributions to the Company during his tenure and wish him continued success in future endeavors.

About Corral Copper

The Corral Copper Property, located near historical mining areas, is an advanced exploration and development opportunity in Cochise County, Arizona. Corral is located 15 miles east of the famous mining town of Tombstone and 22 miles north of the historic Bisbee mining camp which has produced more than 8 billion pounds of copper1. Production from the Bisbee mining camp, or within the district as disclosed in the next paragraph, is not necessarily indicative of the mineral potential at Corral.

The district has a mining history dating back to the late 1800s, with several small mines extracting copper from the area in the early 1900s, producing several thousand tons. Between 1950 and 2008, various companies explored parts of the district, but the effort was uncoordinated, non-synergistic and focused on discrete land positions and commodities due to the fragmented ownership. There is over 50,000m of historical drilling at Corral mainly centered on the Ringo, Earp and Holliday Zones and although this core has been destroyed, Intrepid has a historical digital drill hole archive database which the Company uses for the purposes of exploration targeting and drill hole planning. Intrepid, through ongoing exploration drilling and surface geological mapping, sampling and prospecting is increasing confidence in the validity of this data.

Intrepid is confident that by combining modern exploration techniques with historical data and with a clear focus on responsible development, the Corral Copper Property can quickly become an advanced exploration stage project and move towards development studies.

About Intrepid Metals Corp.

Intrepid Metals Corp. is focused on exploring for high-grade essential metals, including copper, silver, and zinc, in established mining jurisdictions in southeastern Arizona, USA. The Company’s portfolio is anchored by the Corral Copper Project, an advanced exploration-stage, district-scale system with extensive drilling and significant shallow results, complemented by the Tombstone South and Mesa Well projects. Teck Resources Limited recently became a 9.9% equity stakeholder in Intrepid Metals Corp., reflecting its strategic interest in the Company and its Corral Project. Intrepid is led by an experienced technical and management team with a strong track record of advancing and permitting projects across North America. The Company trades on the TSX Venture Exchange under the symbol “INTR” and on the OTCQB Venture Market under the symbol “IMTCF”. For more information, visit www.intrepidmetals.com.

INTREPID METALS CORP.

On behalf of the Company
“Mark J. Morabito”
Chairman & CEO

For further information regarding this news release, please contact:
Mark J. Morabito, Chairman & CEO
604-306-3835
info@intrepidmetals.com

Notes
1 Information disclosed in this news release regarding the historic Bisbee Camp can be found on the Copper Queen Mine website, on the City of Bisbee website (www.bisbeeaz.gov/2174/Bisbee-History) and from Briggs, D.F., 2015, History of the Warren (Bisbee) Mining District, Arizona Geological Survey Contributed Report CR-15-b, 8 p.

Cautionary Note Regarding Forward-Looking Information

Certain statements contained in this release constitute forward-looking information within the meaning of applicable Canadian securities laws. Such forward-looking statements relate to: the potential of Corral; the closing of the Offering; the timing of the closing of the Offering; the use of proceeds from the Offering; the potential of Corral as an emerging copper asset in a highly prospective district; the exploration potential of the Corral Copper Property and the Company’s other mineral projects; and potential future production.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved” suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Forward-looking information contained in this news release is based on certain factors and assumptions regarding, among other things, receipt of all necessary approvals for the Offering, including approval of the TSX Venture Exchange; the Company can raise additional financing to continue operations; the results of exploration activities, commodity prices, the timing and amount of future exploration and development expenditures, the availability of labour and materials, receipt of and compliance with necessary regulatory approvals and permits, the estimation of insurance coverage, and assumptions with respect to currency fluctuations, environmental risks, title disputes or claims, and other similar matters. While the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.

Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to the ability to access infrastructure, risks relating to the failure to access financing, risks relating to changes in commodity prices, risk related to unanticipated geological or structural formations and characteristics risks related to current global financial conditions, risks related to current global financial conditions and the impact of any future global pandemic on the Company’s business, reliance on key personnel, operational risks inherent in the conduct of exploration and development activities, including the risk of accidents, labour disputes and cave-ins, regulatory risks including the risk that permits may not be obtained in a timely fashion or at all, financing, capitalization and liquidity risks, risks related to disputes concerning property titles and interests, environmental risks and the additional risks identified in the “Risk Factors” section of the Company’s reports and filings with applicable Canadian securities regulators.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information is made as of the date of this news release. Except as required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this release.

The issuer is solely responsible for the content of this announcement.

1...1,0601,0611,062...6,466Page 1,061 of 6,466